Patent: 10,350,213
✉ Email this page to a colleague
▶ Start for $1
Remove trial restrictions
Summary for Patent: 10,350,213
| Title: | Methods for treating cancer using apilimod |
| Abstract: | The present invention relates to methods for treating cancer with apilimod and related compositions and methods. |
| Inventor(s): | Lichenstein; Henri (Guilford, CT), Rothberg; Jonathan M. (Guilford, CT), Gayle; Sophia (East Haven, CT), Beeharry; Neil (Guilford, CT), Beckett; Paul (Yorktown Heights, NY), Landrette; Sean (Meriden, CT), Conrad; Chris (Guilford, CT), Xu; Tian (Guilford, CT) |
| Assignee: | AI Therapeutics, Inc. (Guilford, CT) |
| Application Number: | 15/213,829 |
| Patent Claims: | see list of patent claims |
Details for Patent 10,350,213
| Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
|---|---|---|---|---|---|---|---|
| Merck Sharp & Dohme Corp. | KEYTRUDA | pembrolizumab | For Injection | 125514 | 09/04/2014 | See Plans and Pricing | 2039-07-30 |
| Merck Sharp & Dohme Corp. | KEYTRUDA | pembrolizumab | Injection | 125514 | 01/15/2015 | See Plans and Pricing | 2039-07-30 |
| Bristol-myers Squibb Company | OPDIVO | nivolumab | Injection | 125554 | 12/22/2014 | See Plans and Pricing | 2039-07-30 |
| Bristol-myers Squibb Company | OPDIVO | nivolumab | Injection | 125554 | 10/04/2017 | See Plans and Pricing | 2039-07-30 |
| Bristol-myers Squibb Company | OPDIVO | nivolumab | Injection | 125554 | 08/27/2021 | See Plans and Pricing | 2039-07-30 |
| Genentech, Inc. | TECENTRIQ | atezolizumab | Injection | 761034 | 05/18/2016 | See Plans and Pricing | 2039-07-30 |
| Genentech, Inc. | TECENTRIQ | atezolizumab | Injection | 761034 | 03/08/2019 | See Plans and Pricing | 2039-07-30 |
| >Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |
